336 related articles for article (PubMed ID: 21030679)
1. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance.
Hare S; Vos AM; Clayton RF; Thuring JW; Cummings MD; Cherepanov P
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20057-62. PubMed ID: 21030679
[TBL] [Abstract][Full Text] [Related]
2. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
Hu Z; Kuritzkes DR
J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
[TBL] [Abstract][Full Text] [Related]
3. Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.
Johnson BC; Métifiot M; Pommier Y; Hughes SH
Antimicrob Agents Chemother; 2012 Jan; 56(1):411-9. PubMed ID: 22037850
[TBL] [Abstract][Full Text] [Related]
4. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.
Goethals O; Van Ginderen M; Vos A; Cummings MD; Van Der Borght K; Van Wesenbeeck L; Feyaerts M; Verheyen A; Smits V; Van Loock M; Hertogs K; Schols D; Clayton RF
Antiviral Res; 2011 Aug; 91(2):167-76. PubMed ID: 21669228
[TBL] [Abstract][Full Text] [Related]
5. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
Malet I; Delelis O; Valantin MA; Montes B; Soulie C; Wirden M; Tchertanov L; Peytavin G; Reynes J; Mouscadet JF; Katlama C; Calvez V; Marcelin AG
Antimicrob Agents Chemother; 2008 Apr; 52(4):1351-8. PubMed ID: 18227187
[TBL] [Abstract][Full Text] [Related]
6. MK-0536 inhibits HIV-1 integrases resistant to raltegravir.
Métifiot M; Johnson B; Smith S; Zhao XZ; Marchand C; Burke T; Hughes S; Pommier Y
Antimicrob Agents Chemother; 2011 Nov; 55(11):5127-33. PubMed ID: 21876054
[TBL] [Abstract][Full Text] [Related]
7. Impact of resistance mutations on inhibitor binding to HIV-1 integrase.
Chen Q; Buolamwini JK; Smith JC; Li A; Xu Q; Cheng X; Wei D
J Chem Inf Model; 2013 Dec; 53(12):3297-307. PubMed ID: 24205814
[TBL] [Abstract][Full Text] [Related]
8. Close-up: HIV/SIV intasome structures shed new light on integrase inhibitor binding and viral escape mechanisms.
Engelman AN; Cherepanov P
FEBS J; 2021 Jan; 288(2):427-433. PubMed ID: 32506843
[TBL] [Abstract][Full Text] [Related]
9. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation.
Delelis O; Malet I; Na L; Tchertanov L; Calvez V; Marcelin AG; Subra F; Deprez E; Mouscadet JF
Nucleic Acids Res; 2009 Mar; 37(4):1193-201. PubMed ID: 19129221
[TBL] [Abstract][Full Text] [Related]
10. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.
Marinello J; Marchand C; Mott BT; Bain A; Thomas CJ; Pommier Y
Biochemistry; 2008 Sep; 47(36):9345-54. PubMed ID: 18702518
[TBL] [Abstract][Full Text] [Related]
11. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
12. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
Hassounah SA; Alikhani A; Oliveira M; Bharaj S; Ibanescu RI; Osman N; Xu HT; Brenner BG; Mesplède T; Wainberg MA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923862
[TBL] [Abstract][Full Text] [Related]
13. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
Hachiya A; Ode H; Matsuda M; Kito Y; Shigemi U; Matsuoka K; Imamura J; Yokomaku Y; Iwatani Y; Sugiura W
Antiviral Res; 2015 Jul; 119():84-8. PubMed ID: 25956162
[TBL] [Abstract][Full Text] [Related]
14. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
[TBL] [Abstract][Full Text] [Related]
15. Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
Zhao XZ; Maddali K; Metifiot M; Smith SJ; Vu BC; Marchand C; Hughes SH; Pommier Y; Burke TR
Chem Biol Drug Des; 2012 Feb; 79(2):157-65. PubMed ID: 22107736
[TBL] [Abstract][Full Text] [Related]
16. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.
Seki T; Suyama-Kagitani A; Kawauchi-Miki S; Miki S; Wakasa-Morimoto C; Akihisa E; Nakahara K; Kobayashi M; Underwood MR; Sato A; Fujiwara T; Yoshinaga T
Antimicrob Agents Chemother; 2015 May; 59(5):2596-606. PubMed ID: 25691633
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations.
Mouscadet JF; Arora R; André J; Lambry JC; Delelis O; Malet I; Marcelin AG; Calvez V; Tchertanov L
J Mol Recognit; 2009; 22(6):480-94. PubMed ID: 19623602
[TBL] [Abstract][Full Text] [Related]
18. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.
Hu Z; Kuritzkes DR
J Acquir Immune Defic Syndr; 2010 Oct; 55(2):148-55. PubMed ID: 20634701
[TBL] [Abstract][Full Text] [Related]
19. Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site.
Métifiot M; Johnson BC; Kiselev E; Marler L; Zhao XZ; Burke TR; Marchand C; Hughes SH; Pommier Y
Nucleic Acids Res; 2016 Aug; 44(14):6896-906. PubMed ID: 27369381
[TBL] [Abstract][Full Text] [Related]
20. Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis.
Xue W; Jin X; Ning L; Wang M; Liu H; Yao X
J Chem Inf Model; 2013 Jan; 53(1):210-22. PubMed ID: 23231029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]